The efficacy and safety of liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus:a meta-analysis
Objective To evaluate the efficacy and safety of liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus by Meta-analysis.Methods A comprehensive computerized search of the China Biomedical Literature Database(CBM),China Knowledge Internet(CNKI),Wanfang Database,Chinese Science and Technology Journal Database(VIP),PubMed,Embase,The Cochrane Library,and Web of Science was conducted to collect data on the use of liraglutide in combination with acarbose for the treatment of obesity type 2 diabetes mellitus compared with the use of acarbose alone.Randomized controlled trials(RCTs)comparing treatment of obese type 2 diabetes.Meta-analysis was performed using RevMan 5.3 software,with relative risk ratio(RR)as the effect size for dichotomous data and mean difference(MD)as the effect size for continuous data.Results A total of 14 RCTs containing 1,416 patients were included,including 709 in the liraglutide combined with acarbose group and 707 in the acarbose alone group.The results showed that the difference between the liraglutide combined with acarbose group and single acarbose treatment was statistically significant in reducing fasting glucose,2 h postprandial glucose,body mass index,total cholesterol,triglycerides,glycosylated hemoglobin,and insulin resistance index(P<0.05);and there was no statistically significant difference in the incidence of hypoglycemia and the incidence of gastrointestinal system adverse reactions between the two groups(P>0.05).Conclusion Liraglutide combined with acarbose in the treatment of obese type 2 diabetes mellitus is superior to the single use of acarbose in lowering fasting glucose,postprandial 2h glucose,body mass index,total cholesterol,triglyceride,glycosylated hemoglobin,and insulin resistance index,and does not increase the incidence of hypoglycemia and digestive system adverse reactions.
LiraglutideAcarboseObesity type 2 diabetesRandomized controlled trialMeta-analysis
万方数据
维普
